Abstract
Ophthalmology, and in particular retina, has undergone a major transformation with the introduction of anti-VEGF therapies and optical coherence tomography imaging. These two new tools in the armamentarium of ophthalmologists have transformed the options available to physicians and patients, and recovered much more vision than had ever been possible before. Yet many patients still lose vision due to incomplete vision recovery or inability to adhere to treatment schedules. Biotechnology and pharmaceutical companies house the end-to-end drug/device development process from disease mechanism target/candidate product identification through Phase III data generation for health authority review and beyond. This chapter sheds light on the how and why of steps from beginning to end, reviewing key aspects of Phase I–IV clinical trials, and how ophthalmology clinical skills may be applied in satisfying ways to help make the next generation of tools for ophthalmology.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Kaufman EA. Physician Exec. 2001;27(2):80–3.
www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process.
DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–31.
Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248–64.
Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target? Drug Discov Today. 2012;17:S24–30.
DrugBank – www.drugbank.ca.
Lindsay MA. Target discovery. Nat Rev Drug Discov. 2003;2:831–8. https://doi.org/10.1038/nrd1202.
www.fda.gov/patients/drug-development-process/step-3-clinical-research.
Chakravarthy U, Bailey C, Brown D, et al. Phase 1. Ophthalmol Retina. 2017;1(6):474–85. https://doi.org/10.1016/j.oret.2017.03.003. Epub 2017 May 23.
Sahni J, Patel SS, Dugel PU, et al. Boulevard Ph2. Ophthalmology. 2019;126(8):1155–70. https://doi.org/10.1016/j.ophtha.2019.03.023. Epub 2019 Mar 21.
www.covance.com/content/dam/covance/assetLibrary/whitepapers/Regulatory-White-Paper-WPCDS029.pdf.
Christopher D, Breder MP. Design of clinical drug development programs. The Center for Drug Evaluation and Research – FDA; 2010.
Sietsema WK. Strategic clinical development planning designing programs for winning products. Washington Business; 2005.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Fung, A.E., Sahni, J. (2021). Demystifying Pharma and BioTech: Applying Ophthalmology to Make New Tools. In: Weng, C.Y., Berrocal, A.M. (eds) Women in Ophthalmology. Springer, Cham. https://doi.org/10.1007/978-3-030-59335-3_37
Download citation
DOI: https://doi.org/10.1007/978-3-030-59335-3_37
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-59334-6
Online ISBN: 978-3-030-59335-3
eBook Packages: MedicineMedicine (R0)